This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E72.2 | Special Copayment Reduction: V117 |
| B. Synonyms | ASL deficiency, Argininosuccinic aciduria, Argininosuccinate lyase deficiency, ASA lyase deficiency |
| C. Adult onset | Likelihood of first diagnosis in adulthood: present (mild form) — with mild residual ASL activity, it may first present from childhood to adulthood with intermittent hyperammonemia, cognitive decline, and hypertension. In the era before newborn screening, there were many cases diagnosed in adulthood. |
| 1. History | 1958, first described by Allan et al. (patients with excessive urinary excretion of argininosuccinic acid) → ASL enzyme deficiency confirmed in the 1960s → introduction of tandem MS/MS newborn screening → establishment of arginine supplementation therapy → resolution of hyperammonemia after liver transplantation confirmed. |
| 2. Causes | Pathogenic variants in the ASL gene (7cen-q11.2) → blocked breakdown of argininosuccinic acid into arginine and fumarate → accumulation of argininosuccinic acid and ammonia. Autosomal recessive inheritance. |
| 3. Genetics | ASL gene (7q11.21): 16 exons. More than 200 pathogenic variants. The c.1168G>A (p.Glu390Lys) variant is relatively common. Many are compound heterozygous. Residual ASL activity correlates with phenotype. |
| 4. General epidemiology | About 1 in 70,000–218,000 births. The second most common of all UCDs (after OTC deficiency). Included in the tandem MS/MS newborn screening panel (elevated citrulline → confirmatory testing). |
| 5. Pathophysiology | ASL deficiency → argininosuccinic acid accumulation + insufficient arginine supply → incomplete urea synthesis → hyperammonemia. ASL is also present in tissues other than the liver (blood vessels, brain) and is involved in nitric oxide (NO) synthesis (endothelial eNOS) → in ASL deficiency, reduced vascular NO → mechanism of systemic hypertension. Argininosuccinic acid itself may also be neurotoxic. |
| 6. Symptoms | Severe neonatal form: hyperammonemic encephalopathy. Chronic/mild form: cognitive impairment, behavioral problems, hepatomegaly, hypertrophic hepatic fibrosis, hair abnormality (trichorrhexis nodosa), hypertension. Failure to thrive. Intermittent hyperammonemic episodes. |
| 7. Signs | Moderately elevated plasma citrulline, detection of argininosuccinic acid (plasma and urine), elevated urinary orotic acid. Hepatomegaly. Hair microscopy: nodular hair (trichorrhexis nodosa). Elevated blood pressure. |
| 8. Screening | Newborn tandem MS/MS: elevated blood citrulline (usually at 100–300 μmol/L). Confirmatory testing: plasma amino acids (detection of argininosuccinic acid), urinary organic acids (elevated orotic acid), ASL gene testing. |
| 9. Diagnosis | Plasma amino acids (elevated citrulline, argininosuccinic acid positive), urinary organic acids (elevated orotic acid, elevated argininosuccinic acid), blood ammonia, erythrocyte ASL enzyme activity, ASL gene panel NGS. |
| 10. Treatment | Oral arginine supplementation (supports nitrogen excretion via the urea cycle). Low-protein diet. Nitrogen scavengers (sodium benzoate, phenylbutyrate). Acute hyperammonemia: standard emergency management + hemodialysis (severe cases). Liver transplantation (curative treatment). Hypertension: standard antihypertensives. |
| 11. Prognosis | Survival improves with early treatment after newborn screening. However, a distinctive course in which cognitive impairment, hypertension, and hepatic fibrosis progress despite maintenance of normal ammonia. After liver transplantation, hyperammonemia resolves, but extrahepatic symptoms (hypertension, neurological) partly persist. Long-term follow-up required. |
| 12. Prevention | Early diagnosis by newborn screening. Familiarity with emergency management protocols. Early recognition and treatment of hypertension. Regular liver function and hair examinations. Genetic counseling and family screening. |
| 13. References | Nagamani SC et al. Nat Rev Dis Primers. 2012, and 9 others |
Argininosuccinic aciduria was recognized as a clinical disease in 1958, when Allan, Cusworth, Dent, Wilson, and colleagues in the UK first described patients who excreted excessive argininosuccinic acid in the urine. These patients showed intellectual disability along with a peculiar hair abnormality (trichorrhexis nodosa, nodular hair), and biochemical analysis confirmed accumulation of argininosuccinic acid in urine and plasma. At the time, this attracted attention as a new disorder of amino acid metabolism.
In the early 1960s, enzyme studies revealed that deficiency of argininosuccinate lyase (ASL) was the causative enzyme defect. ASL catalyzes the reaction that breaks down argininosuccinic acid into arginine and fumarate, and it was established that deficiency of this enzyme simultaneously causes argininosuccinic acid accumulation and impaired urea synthesis. Thereafter, argininosuccinic aciduria was classified as one of the urea cycle disorders and studied as such.
In the 1970s–80s, the principle that oral arginine supplementation partially restores urea cycle function and promotes ammonia excretion was established and introduced into treatment. Because arginine is an amino acid that is deficient in argininosuccinic aciduria and at the same time is converted to ornithine in the process of urea synthesis to maintain the urea cycle, arginine supplementation has a distinctive therapeutic mechanism in this disease.
The ASL gene is located on chromosome 7 (7q11.21) and was cloned in the 1990s, after which more than 200 pathogenic variants were reported. As newborn screening based on tandem mass spectrometry (MS/MS) expanded in the 2000s, elevated blood citrulline came to be used as an early detection marker, making it possible to start treatment before symptom onset. However, a distinctive course was observed in which cognitive impairment, hypertension, and hepatic fibrosis progress despite early diagnosis and treatment, and it was recognized that ASL deficiency has complex pathology beyond a simple urea cycle enzyme deficiency. Systemic hypertension occurs commonly in argininosuccinic aciduria, and recent studies have elucidated the mechanism by which this is associated with a defect in the role of ASL in nitric oxide (NO) synthesis.
Argininosuccinic aciduria is an autosomal recessive genetic disease caused by deficiency of argininosuccinate lyase (ASL) due to pathogenic variants in the ASL gene (7q11.21). ASL is the 4th enzyme of the urea cycle and catalyzes the reaction that breaks down argininosuccinic acid into arginine and fumarate. When this reaction is blocked, argininosuccinic acid accumulates excessively in plasma and urine, urea synthesis becomes incomplete, and ammonia accumulates. In argininosuccinic aciduria, because arginine is not produced normally, the later step of the urea cycle (arginine → urea + ornithine) is also blocked.
The ASL gene consists of 16 exons, and more than 200 pathogenic variants have been reported to date. Variant types are diverse, including missense, nonsense, splicing variants, and small deletions/insertions. One of the most studied variants is c.1168G>A (p.Glu390Lys), which affects the stability of the enzyme's tetrameric structure. Most patients are compound heterozygous, carrying two different pathogenic variants.
Importantly, ASL is involved not only in urea synthesis in the liver but is also expressed in tissues throughout the body, including vascular endothelial cells, neurons, kidney, and lung. In particular, in endothelial cells ASL forms a functional complex with nitric oxide synthase (eNOS) and is involved in supplying arginine, the substrate of eNOS, thereby promoting nitric oxide (NO) production. In ASL deficiency, arginine supply is also insufficient in extrahepatic tissues and NO synthesis is reduced, which is the key mechanism by which systemic hypertension develops in argininosuccinic aciduria. This explains why vascular hypertension sometimes does not fully resolve even when urea cycle function normalizes after liver transplantation.
The ASL gene is located on the long arm of chromosome 7 (7q11.21), consists of 16 exons, and has a cDNA length of about 1.5 kb. The mature ASL protein has a tetrameric structure composed of 464 amino acids and functions as a homotetramer. The tetrameric structure means that the enzyme active site, which is not observed in the monomer, is located at the monomer interface, so monomer instability caused by variants leads to collapse of the entire tetrameric structure and loss of enzyme activity.
Phenotype–genotype correlations are incomplete, but in general complete-deficiency variants (nonsense, frameshift) tend to be associated with the severe neonatal form, and missense variants that leave residual activity tend to be associated with mild to moderate phenotypes. However, differences in clinical phenotype are observed even with the same genotype, so genetic background (modifier genes) and environmental factors (diet, frequency of infections, etc.) affect the phenotype. In Korea, molecular epidemiological data on the ASL gene are limited, but variants such as c.1168G>A and c.857A>G (p.Tyr286Cys) have been reported in Korean patients.
With autosomal recessive inheritance, each parent of a patient is a heterozygous carrier without clinical symptoms. Each sibling has a 25% risk of being affected. When the familial variant has been identified, prenatal diagnosis can be performed in pregnancy by chorionic villus sampling (CVS, 11–14 weeks of gestation) or amniocentesis (15–20 weeks of gestation). Preimplantation genetic testing (PGT) is also available. ASL gene testing is the standard tool for diagnostic confirmation, genetic counseling, and prenatal diagnosis.
The incidence of argininosuccinic aciduria is estimated at about 1 in 70,000–218,000 newborns, making it the second most common urea cycle disorder (UCD) after OTC deficiency (about 50%). It is known to account for about 15–20% of the overall UCD frequency (about 1 in 35,000). It is one of the main diseases detected by elevated blood citrulline on newborn screening based on tandem mass spectrometry (MS/MS).
The sex distribution is equal (autosomal recessive), and it occurs in all ethnic groups and regions. Before the introduction of tandem MS/MS newborn screening, diagnosis was often delayed due to nonspecific symptoms in childhood such as intellectual disability, hair abnormalities, and hepatomegaly, or it was first diagnosed in adulthood. Currently, in countries with tandem MS/MS screening, most cases are detected in the neonatal period and early treatment is started. In Korea as well, screening for argininosuccinic aciduria is performed as part of the expanded newborn screening program, and it is diagnosed through confirmatory testing when elevated citrulline is found on tandem MS/MS.
A notable epidemiological feature of argininosuccinic aciduria is that, although survival has improved with newborn screening and early treatment, cognitive impairment, systemic hypertension, hepatomegaly, and hepatic fibrosis develop over the long term in a substantial proportion. In data from the US Urea Cycle Disorders Consortium (UCDC), systemic hypertension develops in about 40–50% of patients with argininosuccinic aciduria, and cognitive decline is reported in about 50–70%. This suggests that the extrahepatic pathology of this disease (vascular, nervous system) progresses independently even after treatment.
The pathophysiology of argininosuccinic aciduria is understood along two axes: hyperammonemia due to the urea cycle block, and a defect in the role of ASL in arginine/NO synthesis in extrahepatic tissues.
Mechanism of hyperammonemia: when ASL is deficient, the 4th step of the urea cycle (argininosuccinic acid → arginine + fumarate) is blocked. Because arginine is therefore not produced, the last step of the urea cycle (arginine → urea + ornithine, catalyzed by ARG1) also cannot proceed. Consequently, nitrogen (ammonia) cannot be converted to urea and accumulates in the blood. Blood citrulline rises in argininosuccinic aciduria because citrulline, the substrate of the ASS1 reaction (citrulline + aspartate → argininosuccinic acid), backs up and accumulates due to the downstream block. Urinary orotic acid increases because carbamoyl phosphate overflows into the pyrimidine synthesis pathway.
Mechanism of nitric oxide (NO) synthesis deficiency: ASL is expressed not only in the liver but also in endothelial cells, neurons, kidney, and elsewhere, and in endothelial cells it forms a functional complex (ASL-eNOS channeling complex) with eNOS (endothelial nitric oxide synthase). In this complex, ASL supplies arginine locally to support NO synthesis by eNOS. In ASL deficiency, even if systemic plasma arginine levels are normalized by arginine supplementation, the local supply of arginine near eNOS in tissues is insufficient and NO production is reduced. Reduced NO → impaired vasodilation → systemic hypertension. Oral arginine supplementation is only partially effective in improving systemic blood pressure because of this local NO deficiency mechanism.
Toxicity of argininosuccinic acid itself: there is experimental evidence that argininosuccinic acid itself has independent cytotoxicity. Increased oxidative stress, mitochondrial dysfunction, and induction of DNA damage have been observed. Its possible contribution to the causes of hepatic fibrosis and neurological damage is being studied. If argininosuccinic acid levels remain persistently elevated even when ammonia is controlled by treatment, this toxicity may continue.
In addition to hyperammonemic encephalopathy similar to other urea cycle disorders, the clinical symptoms of argininosuccinic aciduria feature prominent extrahepatic symptoms characteristic of this disease (hypertension, hepatic fibrosis, hair abnormalities, cognitive impairment).
Severe neonatal form: in patients with complete deficiency, hyperammonemic encephalopathy presents within 24–72 hours of birth, progressing sequentially through feeding refusal, lethargy, hypothermia, seizures, hyperventilation, and coma. Without immediate treatment, it results in death or severe neurological damage.
Chronic mild and late-onset forms: when the neonatal period passes uneventfully or symptom onset is delayed, intermittent hyperammonemic episodes (triggered by infection, excessive protein intake, surgery, etc.), failure to thrive, intellectual disability or learning disabilities, and behavioral problems appear during growth or into adulthood. In particular, the appearance of hypertension from childhood is an important feature of argininosuccinic aciduria, occurring at a markedly higher frequency (about 40–50%) than in other UCDs. Because hypertension develops independently of ammonia control, separate attention is needed.
Hair abnormalities: trichorrhexis nodosa is a characteristic clinical finding of argininosuccinic aciduria. On hair microscopy, nodes form at intervals along the hair shaft, and the hair breaks easily at these sites. The exact mechanism of the hair abnormality is unclear but is presumed to be related to impaired synthesis of hair structural proteins due to arginine deficiency. It may improve to some extent with treatment (arginine supplementation).
Liver abnormalities: hepatomegaly and elevated liver enzymes are common, and in some patients hepatic fibrosis progresses and can cause portal hypertension. Rarely, it progresses to cirrhosis. Because liver abnormalities sometimes progress independently of the state of ammonia control, regular liver ultrasound and liver function tests are necessary.
The main diagnostic laboratory findings and physical signs of argininosuccinic aciduria are as follows.
Plasma amino acid abnormalities: the key finding is a moderate elevation of plasma citrulline (usually 100–300 μmol/L, normal < 40 μmol/L). Detection of argininosuccinic acid in plasma and urine is the confirmatory finding of argininosuccinic aciduria. Plasma arginine is normal to low. Elevated glutamine appears when hyperammonemia is present.
Urinary findings: urinary organic acid analysis shows elevated orotic acid, and argininosuccinic acid is excessively excreted in the urine. Argininosuccinic acid is distinguished by its characteristic chromatographic peaks.
Blood ammonia: markedly elevated during acute presentation (hundreds to thousands of μmol/L in the severe neonatal form). In the chronic form, it remains within the normal range and rises during metabolic stress.
Physical findings of the hair: the hair is dry and breaks easily, and trichorrhexis nodosa can be confirmed by light microscopy. This finding is not specific to argininosuccinic aciduria, but when present in a patient with a UCD, it strongly suggests argininosuccinic aciduria.
Blood pressure measurement: systemic hypertension is confirmed. Blood pressure exceeding age-specific normal standards (pediatric percentiles) is commonly found on regular follow-up after the diagnosis of argininosuccinic aciduria. Ambulatory blood pressure monitoring (ABPM) is recommended.
Liver findings: hepatomegaly on abdominal physical examination, increased liver parenchymal echogenicity on abdominal ultrasound (fat deposition, fibrosis), and elevated AST and ALT and elevated bilirubin (severe hepatic fibrosis) on liver function tests are observed.
Argininosuccinic aciduria is included in the newborn screening panel based on tandem mass spectrometry (MS/MS), and elevated blood citrulline is the main screening marker. However, because elevated citrulline is a finding shared with citrullinemia type I (ASS1 deficiency), confirmatory testing after a positive screen is essential.
Newborn tandem MS/MS screening: blood citrulline is measured in a dried blood spot (DBS, collected 48–72 hours after birth). In argininosuccinic aciduria, citrulline is usually elevated to 100–300 μmol/L (in citrullinemia type I it tends to be more markedly elevated, > 300 μmol/L). When citrulline exceeding the screen-positive cutoff is detected, immediate referral for confirmatory testing is needed. Some centers have introduced direct measurement of argininosuccinic acid in the DBS as well to increase specificity.
Confirmatory testing: plasma amino acid chromatography (detection of argininosuccinic acid), urinary organic acid analysis (elevated orotic acid, increased argininosuccinic acid excretion), blood ammonia measurement. When argininosuccinic acid is detected in plasma, argininosuccinic aciduria is confirmed.
Enzyme and genetic testing: ASL enzyme activity is measured in erythrocytes or liver tissue, or pathogenic variants are identified by ASL gene panel NGS. Enzyme activity is useful for determining the presence of residual activity and predicting treatment response. Genetic test results are used for family counseling and prenatal diagnosis.
The diagnosis of argininosuccinic aciduria is made in the following steps.
Step 1 — Biochemical confirmation: the diagnosis is confirmed when argininosuccinic acid is detected along with elevated citrulline on plasma amino acid chromatography (LC-MS/MS or ion exchange). Argininosuccinic acid can be quantified in plasma and urine. Urinary organic acid analysis confirms elevated orotic acid and increased argininosuccinic acid excretion.
Step 2 — Blood ammonia: hyperammonemia is confirmed by measuring blood ammonia in the acute phase or during metabolic stress. In the chronic phase, ammonia may be normal, but regular monitoring is necessary.
Step 3 — Measurement of enzyme activity: ASL enzyme activity is measured in erythrocytes. Because ASL is expressed not only in the liver but also in erythrocytes, there is the advantage that the enzyme can be measured in a blood sample. Enzyme activity below 5% of controls is classified as severe deficiency.
Step 4 — Molecular genetic confirmation: pathogenic variants are identified by ASL gene panel NGS or direct Sanger sequencing. Structural variants such as deletions are further confirmed by MLPA or array CGH. After variant confirmation, the results are used for family genetic counseling, carrier testing, and prenatal diagnosis.
Additional tests: liver ultrasound and liver function (monitoring of hepatic fibrosis), blood pressure measurement and 24-hour ambulatory blood pressure monitoring, neurodevelopmental assessment (cognitive testing, EEG, brain MRI).
Treatment of argininosuccinic aciduria consists of control of hyperammonemia, arginine supplementation, dietary management, and management of extrahepatic complications (hypertension, hepatic fibrosis).
Oral arginine supplementation: in argininosuccinic aciduria, arginine is a conditionally essential amino acid that must be supplemented to maintain urea cycle function. Oral arginine supplementation (usually 100–200 mg/kg/day in divided doses) partially restores nitrogen excretion through the urea cycle and maintains systemic arginine levels. However, as explained above, the defect in NO synthesis by the local eNOS-ASL complex is not fully corrected by systemic arginine supplementation. This is why arginine supplementation does not completely resolve hypertension.
Low-protein diet and amino acid formulas: under the guidance of a specialized metabolic dietitian, natural protein intake is restricted to the minimum range of age-specific protein requirements, and essential amino acid formulas are supplemented. Dietary management to reduce the accumulation of argininosuccinic acid itself is also recommended.
Nitrogen scavengers: sodium benzoate, sodium phenylbutyrate (NaPBA), or glycerol phenylbutyrate (GPB) is added to excrete nitrogen through urea-independent pathways. They are used especially during acute hyperammonemic episodes or in poor chronic control.
Emergency treatment of acute hyperammonemia: stopping protein intake, high-calorie intravenous nutrition, intravenous nitrogen scavengers (sodium benzoate + sodium phenylacetate), and intravenous arginine. In severe cases (blood ammonia > 400 μmol/L, decreased consciousness), continuous renal replacement therapy (CRRT) or hemodialysis is performed.
Treatment of hypertension: when systemic hypertension is confirmed, standard antihypertensives are given (ACE inhibitors or ARBs are somewhat preferred in terms of their interaction with the NO pathway). The blood pressure control target is within the age-specific normal range. The effects of blood pressure control on neurodevelopmental and cardiovascular prognosis are under study.
Liver transplantation: as in severe UCDs, liver transplantation curatively corrects urea cycle function. After liver transplantation, blood ammonia normalizes and protein restriction becomes unnecessary. However, because hypertension and neurological problems due to extrahepatic ASL deficiency may partly persist even after transplantation, multidisciplinary counseling on the timing of transplantation and expected benefits is needed before liver transplantation.
The prognosis of argininosuccinic aciduria is more complex than that of other urea cycle disorders. This is because, although survival has improved greatly with newborn screening and early treatment, extrahepatic complications (hypertension, cognitive impairment, hepatic fibrosis) progress in a substantial proportion despite maintenance of normal ammonia.
Cognitive function and neurodevelopment: even in patients who received early treatment through newborn screening, cognitive impairment (lowered IQ, learning disabilities) and behavioral problems (attention deficit, autism spectrum features) are reported in about 40–70%. This is interpreted as brain damage due to the toxicity of argininosuccinic acid itself and reduced NO synthesis affecting neurodevelopment independently of ammonia toxicity. White matter abnormalities and cortical atrophy are sometimes observed on brain MRI. The frequency and severity of hyperammonemic episodes have the greatest effect on the neurodevelopmental prognosis.
Hypertension and cardiovascular prognosis: despite early treatment, systemic hypertension develops in about 40–50%, and without appropriate blood pressure treatment, target organ damage such as left ventricular hypertrophy and renal failure may occur. When hypertension develops, it is controlled with standard antihypertensives.
Hepatic prognosis: hepatomegaly and elevated liver enzymes are common, and hepatic fibrosis progresses in some. Progression to cirrhosis is rare but has been reported. Monitoring with regular liver ultrasound and liver elastography is recommended.
Prognosis after liver transplantation: after liver transplantation, urea cycle function normalizes and ammonia-related complications resolve. However, hypertension and neurodevelopmental disorders due to extrahepatic ASL deficiency may partly persist after transplantation. Recovery from neurological damage that occurred before transplantation is limited after transplantation.
Prevention in argininosuccinic aciduria consists of early diagnosis by newborn screening, long-term monitoring to prevent complications, and family genetic counseling.
Early diagnosis by newborn screening: early diagnosis through tandem MS/MS newborn screening is the most important preventive strategy. Immediate confirmatory testing and initiation of treatment after a positive screen minimize neurological damage due to severe neonatal hyperammonemia. Because argininosuccinic aciduria is included in Korea's newborn screening program, it is important to check all newborn screening results.
Monitoring for long-term complications: because hypertension, hepatic fibrosis, and cognitive impairment can develop independently in argininosuccinic aciduria even after ammonia is controlled, regular blood pressure measurement (at least twice a year), liver ultrasound (once a year), neurodevelopmental assessment (1–2 times a year), and monitoring of plasma amino acids and ammonia are essential. In particular, early detection and treatment of hypertension are important for preventing cardiovascular and renal complications.
Emergency management protocol: because hyperammonemia can worsen in situations of metabolic stress such as fever, infection, and surgery, all patients and caregivers should be familiar with the emergency management protocol (temporary cessation of protein intake, high-calorie intake, criteria for immediate hospitalization). Carrying a medical alert card and sharing the contact information of the treating metabolic specialist are recommended.
Genetic counseling and family screening: because inheritance is autosomal recessive, both parents of a patient are carriers. Because each sibling has a 25% risk of being affected, newborn screening or confirmation by genetic testing is recommended for siblings. In subsequent pregnancies, prenatal diagnosis (CVS or amniocentesis) or preimplantation genetic testing (PGT) is considered.
Nagamani SC, Erez A, Lee B. Argininosuccinate lyase deficiency. Genet Med. 2012;14(5):501-507. DOI: 10.1038/gim.2011.1. PMID: 22241104.
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019;42(6):1192-1230. DOI: 10.1002/jimd.12100. PMID: 30982989.
Erez A, Nagamani SC, Shchelochkov OA, et al. Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med. 2011;17(12):1619-1626. DOI: 10.1038/nm.2544. PMID: 22081022.
Baruteau J, Jameson E, Morris AA, et al. Progressive neurological symptoms in a teenager: late-diagnosed argininosuccinic aciduria. J Inherit Metab Dis. 2017;40(3):317-318. DOI: 10.1007/s10545-017-0005-3. PMID: 28205030.
Brunetti-Pierri N, Erez A, Shchelochkov O, Craigen W, Lee B. Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency? Mol Genet Metab. 2009;98(1-2):195-197. DOI: 10.1016/j.ymgme.2009.05.002. PMID: 19477679.
Deignan JL, Marescau B, Livesay JC, et al. Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia. Mol Genet Metab. 2008;93(2):172-178. PMID: 17997120.
Lee B, Diaz GA, Rhead W, et al. Portal and systemic ammonia in argininosuccinic aciduria after liver transplantation. Mol Genet Metab. 2013;110(3):315-320. DOI: 10.1016/j.ymgme.2013.06.017. PMID: 23871484.
Tuchman M, Lee B, Lichter-Konecki U, et al. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab. 2008;94(4):397-402. DOI: 10.1016/j.ymgme.2008.05.004. PMID: 18579413.
Kleijer WJ, Garritsen VH, Lindemans J, et al. Prenatal diagnosis of argininosuccinic aciduria: enzyme assay or mutation analysis? Prenat Diagn. 1996;16(5):389-393. PMID: 8809089.
van Ginkel WG, Jahja R, Huijbregts SCJ, et al. Neurocognitive outcome in argininosuccinate lyase deficiency patients treated from newborn screening. Orphanet J Rare Dis. 2016;11(1):67. DOI: 10.1186/s13023-016-0444-8. PMID: 27209214.